Drugs / Nanvuranlat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07265674 | May 2026 → Oct 2027 expected | biliary tract cancer | J-Pharma Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-08-12 | J-Pharma Co., Ltd. | Results Post Hoc Analysis of Nanvuranlat (JPH203) in Advanced Biliary Tract Cancer Published in Cancers — Exploratory Findings to Be Prospectively Evaluated in the Global Phase III Beacon-BTC Study — j-pharma.com ↗
The paper reports exposure–response and subgroup analyses of clinical trial data accumulated to date and identifies scientific hypotheses warranting prospective evaluation in future clinical development. |
| 2025-10-19 | J-Pharma Co., Ltd. | Results 2025 European Society for Medical Oncology (ESMO) Annual Congress: Presentation of Subgroup Analysis Results from the Phase II Clinical Trial of Nanvuranlat Suggesting Patient Selection Criteria for the Global Phase III Clinical Trial j-pharma.com ↗
In intrahepatic cholangiocarcinoma (IHC), extrahepatic cholangiocarcinoma (EHC), and gallbladder cancer (GBC), the nanvuranlat group showed a favorable trend toward prolonged overall survival (OS) compared to the placebo group (hazard ratio = 0.76; 95% confidence interval: 0.46–1.26). |
| 2024-10-01 | J-Pharma Co., Ltd. | Regulatory IND Application to Initiate Clinical Trials of NANVURANLAT for Cancer Patients Approved by U.S. FDA j-pharma.com ↗
We are pleased to announce that the U.S. Food and Drug Administration (FDA) approved our Investigational New Drug (IND) application for a clinical trial of nanvuranlat in cancer patients on September 25, 2024. |
| 2024-09-30 | J-Pharma Co., Ltd. | Results Results of a Phase II Trial of NANVURANLAT in Japan Published in Clinical Cancer Research j-pharma.com ↗
J-Pharma Co. Ltd. announces that the results of the Phase II study of nanvuranlat in Japan have been published in “Clinical Cancer Research” on September 15, 2024. |
| 2023-06-05 | J-Pharma Co., Ltd. | Results LAT1 inhibitor Nanvuranlat (development code: JPH203): Significant improvement in biliary tract cancer with high LAT1 expression, extrahepatic cholangiocarcinoma, and gallbladder cancer j-pharma.com ↗
For advanced and refractory biliary tract cancer, the nanvuranlat group (69 cases) showed a statistically significant improvement in PFS compared to the placebo group (35 cases). |
| 2023-05-26 | J-Pharma Co., Ltd. | Results J-Pharma announces Publication of the Abstract on the Japan Phase 2 study of nanvuranlat (development code: JPH203) for advanced refractory biliary tract cancer patients at the American Society of Clinical Oncology (ASCO) Annual Meeting. Nanvuranlat is an L-type amino acid transporter 1 (LAT1) inhibitor j-pharma.com ↗
In this presentation, when we analyzed the subgroup LAT1 high expression group, we will report that the nanvuranlat administration group showed a statistically significant improvement and a favorable safety profile. |
| 2023-01-23 | J-Pharma Co., Ltd. | Results J-Pharma presented Japanese Phase II Trial of Nanvuranlat at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2023 Nanvuranlat achieved primary endpoint in Japanese Phase II Trial for patients with refractory, advanced biliary tract cancers j-pharma.com ↗
Nanvuranlat, LAT1 Inhibitor, demonstrated a statistically significant progression-free survival with a good safety profile for patients with pretreated advanced refractory biliary tract cancer. |
All press releases naming this drug 21 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanvuranlat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07265674 ↗ |
| Route | Intravenous | “IV administration” NCT07265674 ↗ |